Hannah F. Wright

Hannah F. Wright

Auto-generated profile, based on publicly available information

Hannah F. Wright

Access & Value, Pfizer Ltd, Tadworth, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2022 in Journal of Medical Economics
Verified
Journal Article
Open access
JCJames Campling
James Campling
HWHannah F. Wright
Hannah F. Wright
GHGillian Hall
Gillian Hall
TMTendai Mugwagwa
Tendai Mugwagwa
AVAndrew Vyse
Andrew Vyse
GEGillian F. Ellsbury
Gillian F. Ellsbury
Accurate and up-to-date figures of the cost of community-acquired pneumonia (CAP) hospitalization are needed to understand the associated economic burden for public health decision makers. Recent e...

6 October 2026 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
RBRebecca Butfield
Rebecca Butfield
KRKiran K. Rai
Kiran K. Rai
TJThomas Jennison
Thomas Jennison
JSJack Said
Jack Said
HWHannah Wright
Hannah Wright
DWDexter Wiseman
Dexter Wiseman
Introduction Respiratory syncytial virus (RSV) causes significant disease in older and comorbid adults. Current UK vaccination recommendations restrict eligibility to adults ≥ 75 years, 65–74 years with chronic respiratory disease or immunosuppression, and those in care homes, but evidence on clinical burden in adults < 75 years with comorbidities is limited. This study assessed patient characteristics, healthcare resource utilization (HCRU), and mortality in adults hospitalized with RSV in England. Methods Population-based retrospective cohort study using linked Clinical Practice Research Datalink Aurum and Hospital Episode Statistics. Adults ≥ 60 years hospitalized with RSV between October 2014 and March 2019 were included. We defined RSV episodes as 90 days post-diagnosis. We defined cases using diagnosis codes for confirmed RSV (RSV-specific) or acute lower respiratory tract infection with exclusion of other causative pathogens (RSV-possible). All-cause HCRU (hospitalizations, critical care admissions, outpatient attendance, primary care consultations, and prescriptions) and case fatality rates were assessed. Results were stratified by age (60–74 and ≥ 75 years), case definitions (RSV-specific, RSV-possible), and comorbidity profiles (chronic respiratory disease, immunocompromised, cardiovascular disease). Results A total of 97,712 hospitalized episodes in those aged ≥ 60 years were included in the analysis, of which 785 (0.8%) were RSV-specific cases (n = 338 aged 60–74 years, n = 447 aged ≥ 75 years). In RSV-specific cases, median (IQR) cumulative length of stay (LoS) for those ≥ 75 years was 10.00 (6.00–22.00) days, which was equivalent to or lower than each comorbidity subgroup in those aged 60–74 years, with the longest LoS in those immunocompromised (11.50 [7.00–26.00] days). Critical care admissions were more often observed across comorbidity stratifications (13.85–22.34%) compared to those ≥ 75 years (5.03%). All-cause and RSV-related case fatality rates for RSV-specific cases were highest among those ≥ 75 years (all-cause: 19.3%; RSV-related: 10.3%). Conclusions HCRU within RSV episodes in those aged 60–74 years across comorbidity profiles was equal to or greater than that in those aged ≥ 75 years. These findings highlight the need to prioritize consideration of comorbidity groups that could benefit from RSV vaccination.